The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 06, 2011
Filed:
Jan. 27, 2005
Vladimír Král, Prague, CZ;
Petr Cigler, Ceské Budejovice, CZ;
Jan Konvalinka, Prague, CZ;
Milan Kozísek, Prague, CZ;
Jana Prejdová, Prague, CZ;
Bohumír Grüner, Prague, CZ;
Jaromír Plesek, Prague, CZ;
Martin Lepsík, Prague, CZ;
Jana Pokorná, Prague, CZ;
Hans-georg Kräusslich, Heidelberg, DE;
Jochen Bodem, Heidelberg, DE;
Vladimír Král, Prague, CZ;
Petr Cigler, Ceské Budejovice, CZ;
Jan Konvalinka, Prague, CZ;
Milan Kozísek, Prague, CZ;
Jana Prejdová, Prague, CZ;
Bohumír Grüner, Prague, CZ;
Jaromír Plesek, Prague, CZ;
Martin Lepsík, Prague, CZ;
Jana Pokorná, Prague, CZ;
Hans-Georg Kräusslich, Heidelberg, DE;
Jochen Bodem, Heidelberg, DE;
Vysoka Skola Chemicko-Technologicka V Praze, Prague, CZ;
Ustav Organicke Chemie A Biochemie AV CZ, Prague, CZ;
Ustav Anorganicke Chemie AV CZ, Rez u Prahy, CZ;
Department of Virology, University of Heidelberg, Heidelberg, DE;
Abstract
The present invention provides novel HIV protease inhibitors containing substituted borane, carborane or metallacarborane clusters with 6 to 12 boron atoms in each cluster. The charge of each borane, carborane or metallacarborane cluster is 0, −1 or −2. The number of borane, carborane or metallacarborane clusters in the inhibitor molecule is 1 to 9, and the carborane clusters in metallacarborane inhibitors are coordinated to transition metal atom, selected from the group containing cobalt, iron, nickel and ruthenium. In the cluster, heteroatoms can be present, such as nitrogen, phosphorus, silicon, germanium, tin and sulphur. The present invention covers pharmaceutical compositions containing these inhibitors and their use, both in vitro and in vivo. They are characterized by high effectiveness and stability.